[Interest in agents for adhesion prevention after gynecologic surgery].
Adhesion barriers are intraperitoneal agents, solid or fluid, developed in order to prevent postoperative adhesions. In this article, we evaluate the efficiency of these new barrier agents for adhesion prevention in gynaecologic surgery, undertaking a review of controlled clinical trials published. Several human clinical trials demonstrated the safety and efficiency of both Interceed and Seprafilm. As far as other barrier agents are concerned, data are still insufficient to recommend them for clinical use. There is a need for other randomised controlled trials in order to evaluate functional efficiency of anti adhesion agents.
Ait Menguellet
S
S
Clinique de gynécologie, hôpital Jeanne-de-Flandre, centre hospitalier régional universitaire (CHRU) de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France.
Collinet
P
P
Cosson
M
M
Mariette
C
C
Triboulet
J-P
JP
Vinatier
D
D
D002483:Cellulose, Oxidized / Q000009:adverse effects / Q000627:therapeutic use*; D002584:Cervix Uteri / Q000601:surgery; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D008567:Membranes, Artificial; D011138:Polytetrafluoroethylene / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012449:Safety; D000267:Tissue Adhesions / Q000517:prevention & control*; D016896:Treatment Outcome
D002483:Cellulose, Oxidized; C060002:INTERCEED; D008567:Membranes, Artificial; C118198:Seprafilm; D011138:Polytetrafluoroethylene; D006820:Hyaluronic Acid